Roche Tecentriq clinical study for stage III of urinary skin cancer reaches major endpoint

Recently, Roche, the SwissPharmaceutical(http://giant, announced that IMvigor130, a phase III clinical study on the treatment of urinary skin cancer (UC) on the first line of the PD-L1 tumor immunotherapy tecentriq (UC), had reached a common major endpoint of progression-free survival (PFS)About Tecentriq
Tecentriq is the first approved cancer immunotherapy in bladder cancerCurrently, four ongoing Phase III studies are evaluating Tecentriq as a single-drug therapy and a combination of otherdrug(http://treatment of early and late bladder cancerTecentriq is a monoclonal antibody that targets a protein called PD-L1, expressed on tumor cells and tumor-immersed immune cells, blocking its interaction with PD-1 and B7.1 receptorsBy inhibiting PD-L1, Tecentriq activates T cellsTecentriq has the potential to be the basis for cancer immunotherapy, targeted drugs and various cancer chemotherapy regimensThe studya multicenter, partially blind, randomized Phase III study, which evaluated the efficacy and safety of Tecentriq combined chemotherapy relative to single-use chemotherapy in patients with pre-localized advanced or metastatic urinary disease (mUC) who had not previously received systematic therapy for metastatic diseases 　　The study included 1,213 patients who were randomly assigned to three treatment groups: (1) Tecentriq and platinum-containing chemotherapy (Gisitabine combined with cisplatin or caplatinum) ;(2) Tecentriq, and (3) with platinum chemotherapy (Gisitabine united shuncoa or caplatinum) and placebo (control group) 　　In the Tecentriq joint therapy group, the common primary endpoint was the total survival (OS) and non-progressive survival (PFS) assessed by the study subjects using the solid tumor efficacy evaluation criteria 1.1 (RECIST v1.1) 　　The results showed that Tecentriq combined chemotherapy significantly reduced the risk of disease deterioration or death (PFS) compared to chemotherapy The interim analysis (http:// observed encouraging total lifetime (OS) results, but the data are not yet mature and patients will continue to follow up until the next planned analysis 　　In terms of safety
the safety of the Tecentriq-chemotherapy group was consistent with the safety of a known single drug, and no new safety signals were found in the combination